ISRCTN62346992已完成不适用
A phase I/II study of Olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC)
niversity College London (UK)0 个研究点目标入组 60 人开始时间: 2011年10月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed high risk locally advanced HNSCC (TNM staging T(any) N2 or N3 M0, bulky T3 or T4 N(any) M0) who would normally be offered cisplatin-based radical chemoradiotherapy
- •2. Estimated life expectancy of at least 12 weeks
- •3. WHO performance status of 0 or 1
- •4. Aged more than or equal to 18 years
- •5. Adequate organ function:
- •5.1. Absolute neutrophils =1.5 x 10*9/L
- •5.2. Platelets =100 x 10*9/L
- •5.3. Haemoglobin =10g/dl (to be maintained above 12g/dl whilst on CRT treatment)
- •5.4. Creatinine =1.5 x ULN
- •5.5. Glomerular filtration rate (GFR) =60 ml/min
- •5.6. Serum bilirubin = 1.25 x ULN
- •5.7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x ULN
- •6. Patients willing to use contraception for the duration of the trial and for six months post treatment
- •7. Able to give informed consent
- •8. Patient is willing and able to comply with the protocol for the duration of the study, including the treatment plan investigations required and follow up visits; Target Gender: Male & Female ; Lower Age Limit 18 years
排除标准
- •1. Head & neck cancers of the following types: Nasopharyngeal and paranasal sinus tumours, oral cavity tumours (tumours of the oral cavity)
- •2. Human Papilloma Virus positive oropharyngeal tumours (tonsillar and tongue base tumours)
- •3. Confirmed distant metastatic disease
- •4. Previous chemotherapy or radiotherapy for the treatment of HNSCC tumour
- •5. Previous therapy with a PARP inhibitor
- •6. Previous chemotherapy, immunotherapy or radiotherapy within the last 28 days prior to registration
- •7. Prior history of malignancy, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, breast or prostate, and unless the patient has been free of malignancy for a period of 3 years prior to first dose of trial drug
- •8. Women who are pregnant or lactating
- •9. Pre-existing gastrointestinal disorders that may interfere with the delivery or absorption of trial drugs
- •10. Peripheral neuropathy > Grade 2 (lower grade neuropathy considered significant by treating clinician may be considered an exclusion criterion)
- •11. Significant hearing difficulties (patients with mildly impaired hearing must be made aware of potential ototoxicity)
- •12. Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinician?s judgement, could interfere with patient safety or obtaining informed consent
- •13. Known hepatitis B or C infection
- •14. Immunocompromised patients [e.g. Known human imunodeficiency virus (HIV) positive status]
- •15. Active uncontrolled infection
- •16. The current use of drugs which are known to inhibit Cytochrome P450 3A4 (CYP3A4) which cannot be discontinued for the duration of trial treatment
研究者
相似试验
已完成
1 期
A study for patients with advanced pancreatic cancer looking at adding olaparib to chemotherapy with radiotherapy (chemoradiation)ocally advanced pancreatic cancerCancerISRCTN10361292HS Greater Glasgow and Clyde42
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerEUCTR2019-001745-40-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.300
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancerThe treatment of participants with HRRm and/or HRD-positive cancerMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-503831-17-00Merck Sharp & Dohme LLC425
进行中（未招募）
1 期
Olaparib in combination with pembrolizumab in HRRm and/or HRD positivecancerHRRm and/or HRD-positive cancerMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2019-001745-40-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300